| Followers | 119 |
| Posts | 14218 |
| Boards Moderated | 0 |
| Alias Born | 03/16/2014 |
Wednesday, May 04, 2022 10:24:27 AM
Adding and waiting .
$CTXR
$CTXR
Recent CTXR News
- Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting • PR Newswire (US) • 05/26/2026 12:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/22/2026 09:00:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:41:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 08:31:01 PM
- Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update • PR Newswire (US) • 05/15/2026 08:30:00 PM
- Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update • PR Newswire (US) • 05/15/2026 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2026 08:30:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 08:30:35 PM
- Citius Oncology Ships First International Order of LYMPHIR™ to Europe • PR Newswire (US) • 04/29/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/24/2026 09:00:16 PM
- Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules • PR Newswire (US) • 04/24/2026 08:30:00 PM
- Citius Pharmaceuticals Secures $5M Through Equity Offering • IH Market News • 04/24/2026 02:48:07 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 04/24/2026 01:24:38 PM
- Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules • PR Newswire (US) • 04/24/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/06/2026 08:15:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 08:32:33 PM
- Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development • PR Newswire (US) • 03/31/2026 01:11:00 PM
- Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts • PR Newswire (US) • 03/24/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/10/2026 01:03:55 PM
- Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers • PR Newswire (US) • 03/10/2026 12:47:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2026 02:25:21 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 02/24/2026 01:04:14 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 02/24/2026 01:02:12 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 02/24/2026 01:00:41 PM
- Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program • PR Newswire (US) • 02/24/2026 01:00:00 PM
